We conducted a randomised, double-blind, parallel design study comparing the efficacy and tolerability of the angiotensin II receptor antagonist, losartan, alone or with low-dose hydrochlorothiazide (HCTZ) to the dihydropyridine calcium channel blocker, nifedipine GITS (gastro-intestinal therapeutic system), in elderly patients (у65 years old) with a diastolic blood pressure ( 
Introduction
Treatment of high blood pressure (BP) in patients with essential hypertension has been clearly shown to reduce cardiovascular events (ie, myocardial infarction and stroke). 1 These findings are even more applicable to older individuals in whom the prevalence of cardiovascular disease is much greater and, therefore, the benefits of treatment are potentially more substantial. 2 had DBP reductions of −14, −15, and −15 mm Hg, respectively. There were no significant differences in the DBP response between the treatment groups except at week 4 (P Ͻ 0.05). Similar reductions in systolic BP (SBP) between the two treatment groups were observed at all time points. The percentages of patients in the two treatment groups reaching goal DBP (Ͻ90 mm Hg or DBP у90 mm Hg with a reduction from a baseline of у10 mm Hg) were comparable (81% on the losartan regimen and 90% on the nifedipine GITS regimen). There were significantly more adverse events reported in patients receiving nifedipine GITS when compared to the losartan regimen (54% vs 36%, P Ͻ 0.05). A patient-reported symptom inventory also showed that swollen ankles was bothersome in significantly more patients treated with the nifedipine GITS regimen when compared to the losartan regimen (24% vs 5%, P = 0.001). Thus, in elderly patients with diastolic hypertension, a regimen of losartan alone or with HCTZ has similar efficacy to a regimen of nifedipine GITS with greater tolerability and less symptom bother due to swollen ankles.
improvement in the incidence of stroke and heart attack as well as death due to these cardiovascular complications. [3] [4] [5] While more than 50% of individuals Ͼ65 years of age have isolated systolic or diastolic hypertension 2 the number of patients currently being treated for hypertension is much smaller. 6 There are certainly many reasons older patients are not adequately treated, including access to care, cost of medications and drug-related side effects. [7] [8] [9] Evidence also suggests that medication intolerability can contribute to drug discontinuations. 10 The angiotensin II receptor blocker, losartan, is indicated for the treatment of essential hypertension. By blocking the interaction of angiotensin II with its receptor (AT 1 subtype), losartan reduces BP in a smooth and sustained fashion. In controlled clinical studies, the overall incidence of side effects has been comparable to placebo. 11 As with other anti-hypertensive agents, losartan can be combined with hydrochlorothiazide (HCTZ) to further decrease BP when therapeutic goals have not been achieved with monotherapy. The efficacy of the two agents combined has been shown to be additive. 12 The purpose of this study was to compare the safety, efficacy and tolerability of losartan alone or with HCTZ vs a regimen of nifedipine GITS (GastroIntestinal Therapeutic System) in the treatment of elderly patients (у65 years old) with diastolic hypertension. Nifedipine GITS is a preparation of nifedipine which is formulated as a controlledrelease tablet for once daily dosing. This agent was chosen as a comparator since recent trends in medication choices for elderly individuals with essential hypertension have shown a substantial rise in the use of calcium channel blockers. 13 Study objectives were to determine the ability of these regimens to achieve target BP (DBP Ͻ90 mm Hg) and the overall tolerability of each treatment scheme, as measured by investigator reported adverse events and patient reported quality of life.
Subjects and methods
Participants in this study (n = 140) were men and women aged у65 years with known diastolic hypertension. Twenty-eight clinical centres participated in the study (see Appendix). The protocol was reviewed and approved by Institutional Review Boards for Human Studies at each of the participating sites and written, informed consent was obtained from each participant prior to enrolment. Initial screening involved a medical history, physical examination and basic laboratory studies. Subjects were excluded if they had a history of significant cardiovascular, cerebrovascular, renal or hepatic disease, or secondary hypertension.
Study design
This was a randomised, double-blind, parallel design multicentre clinical trial comparing the antihypertensive efficacy, tolerability and effects on quality of life during therapy with losartan 50 mg alone or with low dose HCTZ (12.5 or 25 mg) vs nifedipine GITS 30, 60, or 90 mg in elderly patients with essential hypertension. All patients were withdrawn from prior anti-hypertensive medications and entered into a 4-week baseline period during which they received one tablet each of placebo matching losartan and nifedipine GITS daily. The patients were monitored every 2 weeks for vital signs and adverse experiences. Laboratory assessment was obtained after 4 weeks on a placebo. Quality of life questionnaires were administered at each study visit.
All clinic personnel responsible for obtaining BP measurements were certified through a standardised training programme using the American Heart Association guidelines for BP measurement. BP was measured in the sitting position after at least 5-min of rest. All measurements were taken 22-26 h after the last dose of study medication. Three readings were taken at 1-min intervals and averaged to provide a mean value.
Patients whose diastolic BP (DBP) measurements were between 95 and 115 mm Hg and did not differ by more than 7 mm Hg at both their 2-and 4-week placebo period visits were deemed eligible for entry into the active treatment period. Each patient was randomised to receive either losartan or nifedipine GITS in double-blind fashion. Evaluations were performed every 4 weeks and included measurements of vital signs, safety monitoring, and quality of life assessment. All observed or volunteered adverse experiences were recorded and a determination was made by the investigator whether they were drugrelated. At the conclusion of the active treatment period a follow-up clinical exam, laboratory safety assessment and quality of life questionnaire were completed.
The goal of the study was to have patients achieve a sitting DBP Ͻ90 mm Hg with active treatment. Therefore, during follow-up if the patients' DBP was у90 mm Hg their dose of study medication was titrated as follows: losartan 50 mg daily → losartan 50 mg/HCTZ 12.5 mg daily → losartan 50 mg/HCTZ 25 mg daily or nifedipine GITS 30 mg daily → 60 mg daily → 90 mg daily. The first titration step usually occurred at week 4 of active treatment although early titration was allowed for patients with DBP Ͼ110 mm Hg after at least 2 weeks of active treatment.
All medication and matching placebo were taken at the same time of day, usually between 8.00 and 10.00 am. To maintain the blinding of patients and investigators as to study drug assignments, medication was dispensed as active drug and matching placebo. Each pill was taken once daily. For example, patients randomised to the losartan regimen initially received losartan 50 mg tablets along with placebo matching nifedipine GITS 30 mg. If dose titration was required, they were provided a single pill containing losartan 50 mg/HCTZ 12.5 mg and placebo matching nifedipine GITS 60 mg. At 8 weeks of treatment, if further dose titration was required the patients were provided losartan 50 mg tablets and HCTZ 25 mg tablets and placebo matching nifedipine GITS 90 mg. Those patients randomised to the nifedipine GITS regimen received active drug along with matching placebo for losartan, losartan/HCTZ and HCTZ, respectively.
Quality of life assessment
A battery of scales questionnaire was used to evaluate differences in health related quality of life. Six domains were included: overall health perceptions, psychological well being, social functioning, sleep disturbance, cognitive functioning, and sexual functioning. A symptom inventory was also used to assess disease and treatment related complaints. Symptom bother was assessed at each visit during the placebo and active treatment periods. The patients were asked to report the amount of bother they experienced from 32 different symptoms by rating them as 'not at all', 'little', 'moderately', 'quite a bit', or 'extremely'. Symptom bother was considered absent if it was reported as 'not at all' or 'little' during the baseline period and present if symptom bother was considered as 'moderately', 'quite a bit' or 'extremely' at any time during the study. A change was defined as the presence of bother from a particular symptom which was absent at baseline but present at any time during the study. For data analysis symptom bother was recorded as present at its first occurrence and was not dependent upon its continuation throughout the study.
Statistical analysis
The study was designed to have 90% power to detect a 5 mm Hg difference between treatment groups in the change from baseline DBP as significant at ␣ Ͻ0.05. All data analysed and presented are based upon all treated patients (intent to treat analysis). For patients who withdrew prior to completion of the study, the last value recorded on treatment was 'carried forward' to each subsequent observation period for inclusion in the analysis. Baseline comparability of the two treatment groups with respect to demographic and clinical characteristics was assessed using Student's t-test and the Fisher Exact Test. Changes in BP were analysed employing the paired t-test for within group differences and analysis of variance (ANOVA) for between group differences. Summary statistics were calculated and comparisons made between the end of baseline and each period of observation for the two treatment regimens (ie, weeks 4, 8, and 12). Differences within and between treatment groups were considered significant at ␣ Ͻ0.05.
The health related quality of life questionnaire was designed to have 95% power to detect a change of 7-13% (depending on the domain) as significant at ␣ Ͻ0.05. Differences between treatment groups for the health related quality of life scales were compared using an ANOVA model and within group changes were analysed using a paired t-test. The domains of general health and sexual functioning were emphasised. A Bonferroni correction for multiplicity was employed for comparing treatments with regard to these two domains and a P Ͻ 0.025 was considered significant. Regarding symptom bother, between group differences were compared using the chi-square test and within group changes were analysed with the McNemar's test. For all symptoms, treatment differences were considered significant at ␣ Ͻ0.05 except for the symptoms of swollen ankles, headache, and flushing, which were prospectively considered to be more likely in nifedipine-treated patients. In this case a Bonferroni correction for multiplicity was employed and a P Ͻ 0.017 was considered significant.
Results

Efficacy of treatment
A total of 140 patients were entered into the trial; 73 patients were randomised to the losartan regimen and 67 patients to the nifedipine GITS regimen. Table 1 provides a summary of the demographic and clinical characteristics of the patients in each treatment group. No significant differences were found between the two treatment groups at baseline. Of the 140 patients who entered the treatment phase, 88% of losartan-treated patients (n = 64) and 90% of nifedipine GITS-treated patients (n = 60) completed the study. Each of the treatment regimens produced a significant fall in both systolic and diastolic BP at week 12. These results are shown in Table 2 . The DBP response at 4 weeks of therapy showed a significantly greater effect with nifedipine GITS 30 mg than with losartan 50 mg (−14 ± 9 vs −10 ± 9 mm Hg, P Ͻ 0.05; Figure 1 ). Subsequent DBP measurements at weeks 8 and 12 of double-blind treatment did not differ. This was in part related to the addition of HCTZ to the losartan regimen or dose titration of nifedipine GITS for patients whose DBP did not fall below 90 mm Hg after 4 weeks of treatment. At the end of the 12-week active treatment period 32 patients (44%) remained on losartan alone and 41 patients (56%) required addition of HCTZ. Twentysix patients (36%) were titrated to losartan 50 mg/HCTZ 12.5 mg and 15 patients (20%) were titrated to losartan 50 mg/HCTZ 25 mg. In the nifedipine GITS-treated patients, 44 (65%) remained on 30 mg daily, 16 patients (24%) were titrated to 60 mg and seven patients (11%) were titrated to 90 mg daily. The number of patients requiring dose titration during the study (losartan regimen 41/73; nifedipine GITS regimen 23/67) was significantly different (P Ͻ 0.01). All patients had a significant fall in DBP during the study regardless of final study medication(s) assignment, as shown in Figure 2 . Those patients who required the last dose titration step tended to have the highest baseline DBP and the smallest decrement in DBP.
Goal BP was prospectively defined as a DBP Ͻ90 mm Hg or DBP у90 mm Hg with a decrease of у10 mm Hg during treatment. The number and percentage of patients achieving goal BP were similar between the two treatment groups. Fifty patients (68%) treated with the losartan regimen achieved a DBP Ͻ90 mm Hg; an additional nine patients (12%) had DBP у90 mm Hg with a decrement of у10 mm Hg. In the nifedipine GITS-treated patients 54 (82%) achieved a DBP Ͻ90 mm Hg with five additional patients (8%) having DBP у90 mm Hg with a decrement of у10 mm Hg. Overall, 59 patients (81%) in the losartan regimen and 59 patients (90%) in the nifedipine GITS regimen achieved goal DBP (P = NS). Analysis of BP responses in whites and African Americans was also conducted. Of the 140 participants in the study 96 were white and 35 were African American. The randomised treatment assignments resulted in 19 African American patients receiving losartan and 16 receiving nifedipine GITS. This analysis was not pre-specified in the protocol and the sample sizes were small. Nonetheless, the decrease in DBP at week 12 was similar between the two racial groups (Table 3) .
Safety and tolerability of treatment
All reported adverse events (which included those considered by the investigators to be drug-related) were significantly more frequent in patients receiving nifedipine GITS than those treated with the losartan regimen (54% vs 36%, P Ͻ0.05). Oedema (losartan 5%, nifedipine 9%), headache (losartan 5%, nifedipine 7%), and diarrhoea (losartan 4%, nifedipine 3%) were the most common adverse events reported. There were no significant differences between treatment groups in the reporting of these specific symptoms. The incidence of oedema with nifedipine did not show a dose dependency. Of the seven patients in whom oedema was reported five patients were receiving 30 mg daily, one patient was taking 60 mg daily and one patient was taking 90 mg daily. Those adverse events which were considered drug-related by the investigators did not differ between the two regimens (losartan 19%, nifedipine 21%). No significant laboratory test abnormalities (including serum potassium and uric acid levels) were noted in patients treated with either the losartan regimen or nifedipine GITS. Sixteen patients discontinued the study prior to its completion. Early withdrawal was attributed to an adverse event in eight of these patients (four each in the losartan and nifedipine-treated groups, respectively). The study subjects were asked to complete a health related quality of life questionnaire at each visit during the study. There were no significant changes from baseline to the end of the study in overall health perception, cognitive functioning, social functioning, sexual functioning and psychological well-being in either treatment group. Nifedipine-treated patients reported significant worsening (P Ͻ 0.05) from baseline for sleep disturbances at weeks 4, 8 and 12. The losartan-treated patients showed no significant changes from baseline in this parameter. The symptom inventory portion of the questionnaire queried participants for the presence of bother due to 32 different symptoms. A change in symptom bother was considered to have occurred if the symptom was absent at baseline but present at any time during the study. Patient-reported symptom bother from swollen ankles was significantly greater with the nifedipine GITS regimen than with the losartan regimen (24% vs 5%, P = 0.001). All other symptoms were reported with equal frequency between the two groups including those due to headache, flushing and sweating (Table 4) .
Discussion
In this study, a regimen of losartan alone or with low-dose HCTZ had similar anti-hypertensive efficacy and better tolerability with respect to symptom bother due to swollen ankles when compared to nifedipine GITS given in step-wise dose increments. The percentage of patients achieving the therapeutic goal of a reduction in DBP to Ͻ90 mm Hg and/or a DBP у90 mm Hg with a decrement of у10 mm Hg was comparable between the two treatment regimens.
The DBP response to losartan 50 mg alone was less than with nifedipine GITS 30 mg and this was reflected in more patients in the losartan regimen requiring addition of low-dose HCTZ to achieve goal BP. This observation could be a function of the protocol's titration at 4 weeks of therapy for those patients with DBP у90 mm Hg or might also be due to a true difference in the anti-hypertensive effects of losartan and nifedipine GITS in elderly subjects. In this latter regard, elderly patients treated with felodipine have been shown to have delayed drug clearance resulting in higher drug levels and a heightened anti-hypertensive response for a given dose of drug.
14 It is not known whether a similar effect may be present with nifedipine. Despite the more frequent addition of HCTZ to losartan-treated patients, this combination was better tolerated than nifedipine GITS based on the incidence of adverse events and symptom bother from swollen ankles.
Calcium channel blockers such as nifedipine GITS have been previously shown to be effective in treating elderly hypertensives, [15] [16] [17] and this efficacy was confirmed in the present study. Based on these prior observations it has also been suggested that calcium channel blockers may be preferred anti-hypertensive agents for elderly hypertensives. Indeed, the use of calcium channel blockers as treatment for elderly hypertensive patients has expanded markedly since their introduction. 13 Agents which interrupt the renin-angiotensin system have also been purported to not have the same BP-lowering effect as calcium channel blockers in this group of patients. 18 This conclusion has been based on the observation that many elderly patients with essential hypertension have lower plasma renin activity and, therefore, may not respond to agents which block the renin-angiotensin system. However, the present study confirms other studies 16, 19, 20 which have shown that interruption of the renin-angiotensin system in combination with a diuretic is an effective treatment scheme for elderly patients with hypertension.
Given the similar BP responses between the two treatment regimens, an important finding of the present study is that the losartan regimen was better tolerated than nifedipine GITS, as indicated by the lower overall incidence of adverse events and less symptom bother due to oedema. Nifedipine GITS treated patients experienced more adverse events, a significantly greater incidence of sleep disturbance, and more symptom bother due to swollen ankles than losartan-treated patients. Other categories assessed by the health related quality of life questionnaires did not differ between the treatment groups. It is noteworthy that oedema was reported as an adverse event by the investigators only onethird as often as patients self-reported symptom bother due to swollen ankles. This observation underscores the fact that adverse events are often underreported and emphasises the importance of good physician-patient communication with regard to drug-related adverse events.
The recent report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) underscores the high prevalence of hypertension in older persons and the importance of its treatment. 21 The Committee considers optimal drug formulations as those which provide 24 h efficacy with once-daily dosing, qualities which are shared by both losartan and nifedipine GITS. The report notes that angiotensin II receptor blockers have similar haemodynamic effects as ACE inhibitors, with fewer side effects. It reaffirms the beneficial effects of thiazide diuretics in the elderly because of their favourable effects on morbidity and mortality. However, we still lack data on renal and cardiac protection effects of angiotensin II receptor blockers which have been clearly shown with ACE inhibitors.
In this study the treatment regimen of losartan with low-dose HCTZ was equally effective as a regimen of nifedipine GITS in elderly patients with elevated DBP. The losartan regimen was better tolerated, as evidenced by a lower overall incidence of adverse events and less symptom bother due to swollen ankles. Therefore, the use of losartan alone or with HCTZ is an effective, well-tolerated treatment regimen for elderly patients with essential hypertension in whom diastolic BP is not reduced by lifestyle modifications alone.
